Prospective effect of norepinephrine infusion in acute renal insufficiency induced by interleukin 2 therapy.
Allaouchiche
B
B
Mercatello
A
A
Tognet
E
E
Négrier
S
S
Moskovtchenko
J F
JF
Franks
C R
CR
Philip
T
T
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000517:prevention & control; D001794:Blood Pressure; D003131:Combined Modality Therapy; D003404:Creatinine / Q000378:metabolism; D004298:Dopamine / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D009638:Norepinephrine / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; D003404:Creatinine; D004298:Dopamine; D009638:Norepinephrine